4//SEC Filing
INFINITY PHARMACEUTICALS, INC. 4
Accession 0001181431-06-052818
CIK 0001113148operating
Filed
Sep 12, 8:00 PM ET
Accepted
Sep 13, 8:00 PM ET
Size
20.5 KB
Accession
0001181431-06-052818
Insider Transaction Report
Form 4
Lee Patrick Pak-Tin
Director
Transactions
- Award
Common Stock
2006-09-12+21,998→ 21,998 total(indirect: By Advent Private Equity Fund III GmbH Co. KG) - Award
Common Stock
2006-09-12+278,646→ 278,646 total(indirect: By Advent Private Equity Fund III B) - Award
Common Stock
2006-09-12+568,657→ 568,657 total(indirect: By Advent Private Equity Fund III A) - Award
Common Stock
2006-09-12+152,888→ 152,888 total(indirect: By Advent Private Equity Fund III D) - Award
Common Stock
2006-09-12+77,727→ 77,727 total(indirect: By Advent Private Equity Fund III C) - Award
Common Stock
2006-09-12+5,499→ 5,499 total(indirect: By Partnership) - Award
Stock Option (right to buy)
2006-09-12+28,125→ 28,125 totalExercise: $15.04Exp: 2016-09-12→ Common Stock (28,125 underlying) - Award
Common Stock
2006-09-12+18,331→ 18,331 total(indirect: By Advent Private Equity Fund III Affiliates)
Footnotes (10)
- [F1]Reflects a 1-for-4 reverse stock split, which became effective on September 12, 2006.
- [F10]The option vests as to 9,375 of the shares on the first anniversary of the grant date, which grant date was September 12, 2006, and the remainder in quarterly installments of 2,343 shares beginning at the end of the first quarter thereafter, provided that the holder continues to serve as a director.
- [F2]The reporting person is a partner of Advent Venture Partners LLP. Advent Venture Partners LLP owns 100% of Advent Management III Limited, which is General Partner of Advent Management III Limited Partnership, which is General Partner of each of Advent Private Equity Fund III 'A', Advent Private Equity Fund III 'B', Advent Private Equity Fund III 'C', Advent Private Equity Fund III 'D' and Advent Private Equity Fund III Affiliates. Advent Venture Partners LLP also owns 100% of Advent Limited. Advent Limited owns 100% of Advent Private Equity GmbH, which is the general partner of Advent Private Equity Fund III GmbH Co. KG. Voting and investment power over the shares held by each of the partnerships constituting Advent Private Equity Fund III is exercised by Advent Venture Partners LLP in its role as manager. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- [F3]Received in exchange for 19,576 shares of Infinity Discovery, Inc. ("IPI") Series B Preferred Stock in connection with the merger of IPI into Infinity Pharmaceuticals, Inc. (the "Merger") based on a conversion ratio of 1.12375. The Series B Preferred Stock had no expiration date.
- [F4]Received in exchange for 2,024,144 shares of IPI Series B Preferred Stock in connection with the Merger based on a conversion ratio of 1.12375. The Series B Preferred Stock had no expiration date.
- [F5]Received in exchange for 65,252 shares of IPI Series B Preferred Stock in connection with the Merger based on a conversion ratio of 1.12375. The Series B Preferred Stock had no expiration date.
- [F6]Received in exchange for 991,844 shares of IPI Series B Preferred Stock in connection with the Merger based on a conversion ratio of 1.12375. The Series B Preferred Stock had no expiration date.
- [F7]Received in exchange for 276,672 shares of IPI Series B Preferred Stock in connection with the Merger based on a conversion ratio of 1.12375. The Series B Preferred Stock had no expiration date.
- [F8]Received in exchange for 544,208 shares of IPI Series B Preferred Stock in connection with the Merger based on a conversion ratio of 1.12375. The Series B Preferred Stock had no expiration date.
- [F9]Received in exchange for 78,304 shares of IPI Series B Preferred Stock in connection with the Merger based on a conversion ratio of 1.12375. The Series B Preferred Stock had no expiration date.
Documents
Issuer
INFINITY PHARMACEUTICALS, INC.
CIK 0001113148
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001113148
Filing Metadata
- Form type
- 4
- Filed
- Sep 12, 8:00 PM ET
- Accepted
- Sep 13, 8:00 PM ET
- Size
- 20.5 KB